Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters

A. L. Heffernan, T. K. Cunningham, D. S. Drage, L. L. Aylward, K. Thompson, S. Vijayasarathy, J. F. Mueller, Stephen Atkin, T. Sathyapalan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Women with polycystic ovarian syndrome (PCOS) undergoing treatment for infertility could be a sensitive subpopulation for endocrine effects of exposure to perfluorinated alkyl acids (PFAAs), persistent organic pollutants with potential endocrine activity. Women with, PCOS (n = 30) and age- and BMI-matched controls (n = 29) were recruited from a UK fertility clinic in 2015. Paired serum and follicular fluid samples were collected and analysed for 13 PFAAs. Sex steroid and thyroid hormones, and metabolic markers were measured and assessed for associations with serum PFAAs. Four PFAAs were detected in all serum and follicular fluid samples and concentrations in the two matrices were highly correlated (R2 > 0.95): perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), perfluorohexane sulfonate (PFHxS), and perfluorononanoic acid (PFNA). Serum PFOS was positively associated with age (1 ng/mL per yr, p < 0.05) and was higher in PCOS cases than controls (geometric mean [GM] 3.9 vs. 3.1 ng/mL, p < 0.05) and in women with irregular vs. regular menstrual cycles (GM 3.9 vs. 3.0 ng/mL, p = 0.01). After adjustment for confounders, serum testosterone was significantly associated with PFOA, PFHxS, PFNA, and the molar sum of the four frequently detected serum PFAAs (approximately 50 percent increase per ln-unit) among controls but not PCOS cases. HbA1c in PCOS cases was inversely associated with serum PFOA, PFHxs, and sum of PFAAs (2–3 mmol/mol per ln-unit). In controls, fasting glucose was positively associated with serum PFOA and sum of PFAAs (0.25 nmol/L per ln-unit increase in PFAAs). Few other associations were observed. The analyses and findings here should be considered exploratory in light of the relatively small sample sizes and large number of statistical comparisons conducted. However, the data do not suggest increased sensitivity to potential endocrine effects of PFAAs in PCOS patients.

Original languageEnglish
Pages (from-to)1068-1075
Number of pages8
JournalInternational Journal of Hygiene and Environmental Health
Volume221
Issue number7
DOIs
Publication statusPublished - 1 Aug 2018

Fingerprint

Follicular Fluid
Polycystic Ovary Syndrome
perfluorooctanoic acid
Fertility
Acids
Serum
Therapeutics
Gonadal Steroid Hormones
Menstrual Cycle
Thyroid Hormones
Sample Size
Infertility
Testosterone
Fasting
Glucose

Keywords

  • Endocrine disrupting chemicals
  • IVF
  • PCOS
  • Perfluorinated alkyl acids
  • PFAA
  • PFHxS
  • PFNA
  • PFOA
  • PFOS
  • Polycystic ovary syndrome

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters. / Heffernan, A. L.; Cunningham, T. K.; Drage, D. S.; Aylward, L. L.; Thompson, K.; Vijayasarathy, S.; Mueller, J. F.; Atkin, Stephen; Sathyapalan, T.

In: International Journal of Hygiene and Environmental Health, Vol. 221, No. 7, 01.08.2018, p. 1068-1075.

Research output: Contribution to journalArticle

Heffernan, A. L. ; Cunningham, T. K. ; Drage, D. S. ; Aylward, L. L. ; Thompson, K. ; Vijayasarathy, S. ; Mueller, J. F. ; Atkin, Stephen ; Sathyapalan, T. / Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters. In: International Journal of Hygiene and Environmental Health. 2018 ; Vol. 221, No. 7. pp. 1068-1075.
@article{fefca4121ce148c69cc97df7bf9be096,
title = "Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters",
abstract = "Women with polycystic ovarian syndrome (PCOS) undergoing treatment for infertility could be a sensitive subpopulation for endocrine effects of exposure to perfluorinated alkyl acids (PFAAs), persistent organic pollutants with potential endocrine activity. Women with, PCOS (n = 30) and age- and BMI-matched controls (n = 29) were recruited from a UK fertility clinic in 2015. Paired serum and follicular fluid samples were collected and analysed for 13 PFAAs. Sex steroid and thyroid hormones, and metabolic markers were measured and assessed for associations with serum PFAAs. Four PFAAs were detected in all serum and follicular fluid samples and concentrations in the two matrices were highly correlated (R2 > 0.95): perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), perfluorohexane sulfonate (PFHxS), and perfluorononanoic acid (PFNA). Serum PFOS was positively associated with age (1 ng/mL per yr, p < 0.05) and was higher in PCOS cases than controls (geometric mean [GM] 3.9 vs. 3.1 ng/mL, p < 0.05) and in women with irregular vs. regular menstrual cycles (GM 3.9 vs. 3.0 ng/mL, p = 0.01). After adjustment for confounders, serum testosterone was significantly associated with PFOA, PFHxS, PFNA, and the molar sum of the four frequently detected serum PFAAs (approximately 50 percent increase per ln-unit) among controls but not PCOS cases. HbA1c in PCOS cases was inversely associated with serum PFOA, PFHxs, and sum of PFAAs (2–3 mmol/mol per ln-unit). In controls, fasting glucose was positively associated with serum PFOA and sum of PFAAs (0.25 nmol/L per ln-unit increase in PFAAs). Few other associations were observed. The analyses and findings here should be considered exploratory in light of the relatively small sample sizes and large number of statistical comparisons conducted. However, the data do not suggest increased sensitivity to potential endocrine effects of PFAAs in PCOS patients.",
keywords = "Endocrine disrupting chemicals, IVF, PCOS, Perfluorinated alkyl acids, PFAA, PFHxS, PFNA, PFOA, PFOS, Polycystic ovary syndrome",
author = "Heffernan, {A. L.} and Cunningham, {T. K.} and Drage, {D. S.} and Aylward, {L. L.} and K. Thompson and S. Vijayasarathy and Mueller, {J. F.} and Stephen Atkin and T. Sathyapalan",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.ijheh.2018.07.009",
language = "English",
volume = "221",
pages = "1068--1075",
journal = "International Journal of Hygiene and Environmental Health",
issn = "1438-4639",
publisher = "Urban und Fischer Verlag Jena",
number = "7",

}

TY - JOUR

T1 - Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters

AU - Heffernan, A. L.

AU - Cunningham, T. K.

AU - Drage, D. S.

AU - Aylward, L. L.

AU - Thompson, K.

AU - Vijayasarathy, S.

AU - Mueller, J. F.

AU - Atkin, Stephen

AU - Sathyapalan, T.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Women with polycystic ovarian syndrome (PCOS) undergoing treatment for infertility could be a sensitive subpopulation for endocrine effects of exposure to perfluorinated alkyl acids (PFAAs), persistent organic pollutants with potential endocrine activity. Women with, PCOS (n = 30) and age- and BMI-matched controls (n = 29) were recruited from a UK fertility clinic in 2015. Paired serum and follicular fluid samples were collected and analysed for 13 PFAAs. Sex steroid and thyroid hormones, and metabolic markers were measured and assessed for associations with serum PFAAs. Four PFAAs were detected in all serum and follicular fluid samples and concentrations in the two matrices were highly correlated (R2 > 0.95): perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), perfluorohexane sulfonate (PFHxS), and perfluorononanoic acid (PFNA). Serum PFOS was positively associated with age (1 ng/mL per yr, p < 0.05) and was higher in PCOS cases than controls (geometric mean [GM] 3.9 vs. 3.1 ng/mL, p < 0.05) and in women with irregular vs. regular menstrual cycles (GM 3.9 vs. 3.0 ng/mL, p = 0.01). After adjustment for confounders, serum testosterone was significantly associated with PFOA, PFHxS, PFNA, and the molar sum of the four frequently detected serum PFAAs (approximately 50 percent increase per ln-unit) among controls but not PCOS cases. HbA1c in PCOS cases was inversely associated with serum PFOA, PFHxs, and sum of PFAAs (2–3 mmol/mol per ln-unit). In controls, fasting glucose was positively associated with serum PFOA and sum of PFAAs (0.25 nmol/L per ln-unit increase in PFAAs). Few other associations were observed. The analyses and findings here should be considered exploratory in light of the relatively small sample sizes and large number of statistical comparisons conducted. However, the data do not suggest increased sensitivity to potential endocrine effects of PFAAs in PCOS patients.

AB - Women with polycystic ovarian syndrome (PCOS) undergoing treatment for infertility could be a sensitive subpopulation for endocrine effects of exposure to perfluorinated alkyl acids (PFAAs), persistent organic pollutants with potential endocrine activity. Women with, PCOS (n = 30) and age- and BMI-matched controls (n = 29) were recruited from a UK fertility clinic in 2015. Paired serum and follicular fluid samples were collected and analysed for 13 PFAAs. Sex steroid and thyroid hormones, and metabolic markers were measured and assessed for associations with serum PFAAs. Four PFAAs were detected in all serum and follicular fluid samples and concentrations in the two matrices were highly correlated (R2 > 0.95): perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), perfluorohexane sulfonate (PFHxS), and perfluorononanoic acid (PFNA). Serum PFOS was positively associated with age (1 ng/mL per yr, p < 0.05) and was higher in PCOS cases than controls (geometric mean [GM] 3.9 vs. 3.1 ng/mL, p < 0.05) and in women with irregular vs. regular menstrual cycles (GM 3.9 vs. 3.0 ng/mL, p = 0.01). After adjustment for confounders, serum testosterone was significantly associated with PFOA, PFHxS, PFNA, and the molar sum of the four frequently detected serum PFAAs (approximately 50 percent increase per ln-unit) among controls but not PCOS cases. HbA1c in PCOS cases was inversely associated with serum PFOA, PFHxs, and sum of PFAAs (2–3 mmol/mol per ln-unit). In controls, fasting glucose was positively associated with serum PFOA and sum of PFAAs (0.25 nmol/L per ln-unit increase in PFAAs). Few other associations were observed. The analyses and findings here should be considered exploratory in light of the relatively small sample sizes and large number of statistical comparisons conducted. However, the data do not suggest increased sensitivity to potential endocrine effects of PFAAs in PCOS patients.

KW - Endocrine disrupting chemicals

KW - IVF

KW - PCOS

KW - Perfluorinated alkyl acids

KW - PFAA

KW - PFHxS

KW - PFNA

KW - PFOA

KW - PFOS

KW - Polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=85050092903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050092903&partnerID=8YFLogxK

U2 - 10.1016/j.ijheh.2018.07.009

DO - 10.1016/j.ijheh.2018.07.009

M3 - Article

VL - 221

SP - 1068

EP - 1075

JO - International Journal of Hygiene and Environmental Health

JF - International Journal of Hygiene and Environmental Health

SN - 1438-4639

IS - 7

ER -